Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cidara Therapeutics (CDTX) EPS (Weighted Average and Diluted): 2019-2024

Historic EPS (Weighted Average and Diluted) for Cidara Therapeutics (CDTX) over the last 6 years, with Dec 2024 value amounting to -$26.82.

  • Cidara Therapeutics' EPS (Weighted Average and Diluted) fell 26.53% to -$3.10 in Q3 2025 from the same period last year, while for Sep 2025 it was -$10.62, marking a year-over-year increase of 60.02%. This contributed to the annual value of -$26.82 for FY2024, which is 367.25% down from last year.
  • As of FY2024, Cidara Therapeutics' EPS (Weighted Average and Diluted) stood at -$26.82, which was down 367.25% from -$5.74 recorded in FY2023.
  • Over the past 5 years, Cidara Therapeutics' EPS (Weighted Average and Diluted) peaked at -$0.48 during FY2022, and registered a low of -$26.82 during FY2024.
  • In the last 3 years, Cidara Therapeutics' EPS (Weighted Average and Diluted) had a median value of -$5.74 in 2023 and averaged -$11.01.
  • Per our database at Business Quant, Cidara Therapeutics' EPS (Weighted Average and Diluted) spiked by 55.00% in 2021 and then plummeted by 1,095.83% in 2023.
  • Cidara Therapeutics' EPS (Weighted Average and Diluted) (Yearly) stood at -$1.80 in 2020, then skyrocketed by 55.00% to -$0.81 in 2021, then soared by 40.74% to -$0.48 in 2022, then tumbled by 1,095.83% to -$5.74 in 2023, then tumbled by 367.25% to -$26.82 in 2024.